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ABSTRACT
Purpose Basal insulins with improved kinetic properties can
potentially be produced using acylation by fatty acids that enable
soluble, high-molecular weight complexes to form post-
injection. A series of insulins, acylated at B29 with fatty acids via
glutamic acid spacers, were examined to deduce the structural
requirements.
Methods Self-association, molecular masses and hexameric
conformations of the insulins were studied using size exclusion
chromatography monitored by UV or multi-angle light scattering
and dynamic light scattering, and circular dichroism spectroscopy
(CDS) in environments (changing phenol and zinc concentration)
simulating a pharmaceutical formulation and changes following
subcutaneous injection.
Results With depletion of phenol, insulin degludec and another
fatty diacid–insulin analogue formed high molecular mass
filament-like complexes, which disintegrated with depletion of
zinc. CDS showed these analogues adopting stable T3R3 con-
formation in presence of phenol and zinc, changing to T6 with
depletion of phenol. These findings suggest insulin degludec is
dihexameric in pharmaceutical formulation becoming multi-
hexameric after injection. The analogues showed weak dimeric
association, indicating rapid release of monomers following
hexamer disassembly.
Conclusions Insulins can be engineered that remain soluble but
become highly self-associated after injection, slowly releasing
monomers; this is critically dependent on the acylation moiety.
One such analogue, insulin degludec, has therapeutic potential.
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INTRODUCTION
Insulin analogues have been used clinically since the late
1990s. The reason why human insulin is modified for exog-
enous subcutaneous injection therapy is to produce absorp-
tion kinetics that better match the rate of supply from the
injection depot to dynamic physiological need (1).
Naturally, insulin self-associates into dimers, three of which
will combine with two zinc ions to form a hexameric complex,
believed to be an adaption to maximise storage within beta-cell
vesicles (1,2). With exocytosis (and subsequent dilution) these
hexamers rapidly dissociate into biologically active monomers.
When insulin is formulated for clinical use, however, a tolerable
injection volume requires a concentration at which insulin is
naturally hexameric. Thus, pharmaceutical preparations of
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insulin are injected as hexamers, which are too large to readily
pass through capillary fenestrae, but the insulin eventually
dissociates within the injection depot to be absorbed into the
circulation, primarily as dimeric or monomeric units (2). The
first insulin analogues were designed to have weaker self-
association properties to allow more rapid absorption to co-
ordinate the rise in plasma insulin levels with postprandial
glucose absorption (3).
In the case of basal insulin development, the challenge
has been to retard absorption to a greater extent than occurs
with human insulin – ideally to produce a constant, peak-
less kinetic profile that mimics normal basal insulin secre-
tion. The products currently available for clinical use
achieve their prolonged action through a variety of mecha-
nisms, including poorly soluble insulin–protamine (NPH
insulin) or high zinc formulations (Lente insulin), pH-
dependent precipitation (insulin glargine) and local albumin
binding (insulin detemir) (4). Although these mechanisms
prolong the absorption kinetics of these products compared
to regular human insulin, none give an ideal absorption
profile. The original human insulin-based products, such
as NPH insulin, had suboptimal pharmacokinetic (PK) pro-
files, characterised by inappropriate peaks of action coupled
with high variability from injection to injection, both of
which can lead to hypoglycaemia and oblige twice-daily
dosing (1,5,6). The two available insulin analogues (glargine
and detemir) have improved profiles (5), but rising glycae-
mia during the day-time, seen especially when they are used
with rapid-acting mealtime insulins in insulinopenic diabe-
tes, indicates a waning of effect with once-daily dosing (7).
Another limitation of existing basal insulin analogues is that
they are not available as combination formulations with fast-
acting insulin analogues.
The achievement of a truly stable 24-hour basal blood
glucose-lowering effect will require the development of an
insulin that achieves steady state pharmacokinetics with a low
peak:trough ratio, and for this to be achieved with a dosing
frequency that does not exceed once daily, the total duration of
action will need to comfortably exceed 24 h. Furthermore, a
truly stable basal blood glucose-lowering profile will require the
insulin to have low variability of action from injection to injec-
tion, and this goal is likely to be compromised by precipitation
and subsequent redissolution.
To develop a basal insulin fulfilling these criteria, a novel
mechanism of protraction is needed. Because subcutaneous
absorption rate correlates closely with molecular size, insu-
lins capable of forming higher molecular weight multi-
hexameric complexes that remain soluble could provide a
new approach to protracting subcutaneous absorption. This
in turn, however, would require attaching ligands to the
insulin molecule that were capable of linking hexamers to
each other, and for this process to succeed an understanding
of hexameric conformation is critical. The insulin hexamer
can exist in different conformational states according to
whether residues 1–6 of the B-chains (F–L, Fig. 1) of the
constituent monomers are in a tense (T) or relaxed (R)
conformation (8,9). This process is driven by binding of
phenol and anion (chloride) ligands and spectroscopy studies
have suggested three possible conformations for the insulin
hexamer: R6 in which both poles of the hexamer are closed,
R3T3 in which one pole is closed and the other open, and T6
in which both poles are open (Fig. 2). The significance of this
is that the nature of any interactions occurring between the
hexamers of an insulin analogue that involve contact be-
tween the artificial ligand moieties and potential binding
sites on other hexamers are likely to differ depending on
conformational state, i.e. whether the amino acid residues
and/or zinc ions situated in the hexamer cores are exposed
(T conformation) or shielded (R conformation).
A previous study involving acylation of insulin with cholic
acid ligands via a glutamic acid spacer indicated that high
molecular weight insulin complexes could be formed and
the duration of action of the insulin significantly increased
(10). It was therefore speculated that acylation of insulin in this
way with a tailored side-chain could provide a molecular
approach to engineer insulin analogues that would form mul-
tihexamers with ultra-long durations of action. The present
paper reports a series of investigative studies designed to
determine the relevant physico-chemical properties of a series
of insulin analogues thought potentially capable of hexamer–
hexamer interaction and multihexamer formation. The ulti-
mate goal was to identify candidate molecules with potential
for clinical development. To this end, several acylated insulin
analogues were constructed and studied in a series of in vitro
experiments, involving circular dichroism spectroscopy
(CDS), size exclusion chromatography (SEC) and multi-
angle light scattering (MALS). These studies were designed
to characterise the molecular self-association states and hex-
americ conformation (with reference to human insulin and
Fig. 1 Schematic representation of insulin degludec. DesB30 human
insulin was acylated at the ε-amino group of LysB29 with hexadecandioic
acid via a γ-L-glutamic acid linker. The structural elements of the ligand
were examined for their impact on the ability of the resulting insulin
analogue to form multihexamers (Table I).
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comparator analogues) in environments (of varying phenol
and zinc content) designed to simulate the pharmaceutical
formulation and subcutaneous injection depot.
MATERIALS AND METHODS
Preparations, Formulation, and Labelling of Insulin
Analogues
Insulin analogues were prepared by acylations (with fatty-acid
based ligands) of the ε-amino group of LysB29 of biosynthetic
desB30 human insulin. The ligands were composed of fatty
acids or fatty diacids carrying a glutamic acid spacer molecule
and attached to LysB29 by an amide bond (Fig. 1). The ligands
were coupled by peptide bonds as described previously (11).
Formulations for SEC-analysis and SEC-MALS were pre-
pared by suspension of the appropriate insulin analogues,
which were dissolved by addition of dilute sodium hydroxide
before addition of the pharmaceutical excipients in the fol-
lowing order: glycerol 1.7%, 16mMm-cresol, 16mMphenol
and zinc acetate to a final concentration of two or six zinc ions
per six insulin monomers. The pH value was then adjusted to
7.4. In addition, formulated samples of insulin analogues for
human serum albumin binding assays were labelled by 125I2
iodination of TyrA14 (12).
Circular Dichroism Spectroscopy Studies
CDS was used to assess the conformation of insulin hexamers
(including changes following loss of pharmaceutical preserva-
tives), as well as the relative propensity of monomers to remain
self-assembled as dimers. Insulin-zinc hexamers are ordinarily
organised in a T6 confirmation, but with the addition of
chloride and phenol (as in a pharmaceutical formulation) this
conformation can change to T3R3 and R6 states (13). The
phenol concentration of the medium was therefore varied to
assess whether conformational changes take place between
conditions designed to simulate those encountered in the
cartridge of a clinical formulation, and those in the subcuta-
neous environment following injection, where phenol is
expected to diffuse away from the depot (4). Conformational
changes were followed using 251 nm CDS-intensity as previ-
ously described (13). Samples of 0.6 mM insulin, 10 mMTris-
perchlorat buffer, pH 8.0, 0.6 mM zinc acetate and phenol
concentrations varying from 0–30mMwere prepared. Phenol
was added to the insulin solution before zinc acetate. The
disassembly of insulin into monomers was assessed by probing
the tyrosine chromophores at 276 nm as previously described
(14). For this purpose, samples of insulin analogues were
prepared in appropriate concentrations ranging from 5–
2000 μM in 10 mM Tris-perchlorat buffer, pH 7.4. CDS
monitoring of this dilution series was used to identify the
concentration at which the monomeric state was reached.
Size-Exclusion Chromatography Studies
SEC experiments monitored by UV-absorbance were per-
formed to characterise the molecular size of self-assembled
units of the candidate insulins and references, specifically to
evaluate their ability to form insulin dihexamers and multi-
hexamers in the presence of zinc ions. Again, phenol concen-
trations were varied to simulate conditions before and
following subcutaneous injection, and zinc concentrations
were varied to determine the role of zinc in enabling the
formation of complexes. Acylated analogues and human
Fig. 2 Schematic representation
of insulin-zinc hexamer confor-
mation. In a typical pharmaceuti-
cal formulation insulin adopts the
relaxed (R) conformation. Upon
depletion of phenol after injection
the poles will subsequently (one
pole at a time) adopt the tense
(T) conformation, exposing the
core and zinc ions. Ultimately zinc
dissociates and the hexamer dis-
assembles into dimers and insulin
monomers.
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insulin were compared in this model to determine whether
any observed properties would be common to all analogues
featuring a diacid and/or spacer and/or whether the acylated
fatty acid chain length was relevant in determining self-
association profile.
Samples of human insulin, or insulin analogue, in a formu-
lation containing from zero to six zinc ions per six insulin
monomers and 16 mM phenol and 16 mM m-cresol (to
simulate conditions following subcutaneous injection), were
subjected to SEC at 37 °C using a Superose 6PC (0.32×30)
cm and Superose 6HR (1×30)cm (separation range 5×103–
5×106D determined for spherical proteins, GE Lifesciences,
USA). The Superose 6PC column was eluted 50 μL/min and
the Superose 6HR column was eluted with a flow of 250 μL/
min employing phenol-free buffer comprising NaCl 140 mM,
NaN3 1.54 mM and Tris–HCl 10 mM, pH 7.4 (4). The
effluent was monitored at 276 nm, and injection volume was
20 μL and 200 μL respectively. The apparent molecular
masses of the chromatographic peaks were estimated from a
standard curve (15) employing as references: Blue Dextran,
Thyroglobulin, Ferritin, HSA, Co(III)insulin hexamer (16) and
X2 (monomeric AspB9,GluB27 human insulin) (3).
The analysis was repeated with phenol added to the
elution buffer to a final concentration of 2 mM employing
a related column (Superose 12® (1×30)cm GL separation
range 1×103–3×105D determined for spherical proteins,
GE Healthcare, USA) to simulate the composition of a
pharmaceutical insulin formulation (10).
Light-Scattering Studies
SEC-MALS analysis was carried out employing a high per-
formance liquid chromatography (HPLC) system connected
to a DAWN® HELEOS™ MALS detector followed by a
WyattQELS™ dynamic light scattering detector (DLS), and
an Optilab® rEX™ refractive Index (RI) detector. ASTRA®
V software was used to analyse data. The detectors and
software were obtained from Wyatt Technology Inc., Santa
Barbara, CA, USA. For proteins, a typical refractive index
increment value (dn/dc) of 0.185 is used (17–19).
Albumin-Binding Studies
Since albumin binding at the depot and in the circulation
contributes to the prolonged kinetics of insulin detemir (4),
the albumin-binding affinities of the study analogues were
also measured and assessed in proportion to that of insulin
detemir. Binding to HSA was determined as previously
described (20). Human fatty-acid-free serum albumin was
immobilised to divinylsulfone-activated Sepharose 6B Mini-
Leak (Kem-En-Tec, Copenhagen, Denmark), to a concen-
tration of 0.2 mM suction dried gel. The immobilised HSA
was suspended and diluted to cover the range 0–10 μM in
100 mM Tris–HCl, pH 7.4, containing 0.025 % Triton X-
100 to prevent non-specific adhesion. After incubation for
2 h at 23 °C, free and albumin-bound analogue were
separated by centrifugation. Plots of bound/free analogue
vs. albumin concentration were linear and the association







SEC data showing the ability of zinc hexamers of insulin
analogues to self assemble are presented in Table I. SEC
analysis of formulations containing six zinc ions per six
insulin molecules in phenol-free buffer showed that the
presence of a lengthy (≥16 carbon atoms) diacid plus gluta-
mic acid spacer bestowed the analogue with an ability to
form large multihexamer complexes (Table I). Thus, insulin
acylated by hexadecandioyl-γ-L-Glu (insulin degludec) and
octadecandioyl-γ-L-Glu formed multihexamers with an ap-
parent molecular weight (MW) >5 MDa.
Changing the terminal carboxylic acid of the insulin ligand
to 16-hydroxyhexadecanoyl-γ-L-Glu- or hexadecanoyl-γ-L-
Glu desB30 human insulin disrupted the ability to formmulti-
hexamers. The more hydrophobic hexadecanoyl-γ-L-Glu
desB30 human insulin was also unable to form multihex-
amers. Furthermore, changing attachment of the glutamic
acid spacer molecule to hexadecandioyl-α-L-Glu, or substitu-
tion of the spacer molecule by its D-form (hexadecandioyl -γ-
D-Glu), also disrupted mutihexamer formation (Table I).
When SEC was repeated using the same formulations,
but with zinc content reduced to two zinc ions per six insulin
molecules, the analogues displayed similar ranking in terms
of the relative molecular masses of the largest elution peaks
obtained, but with weaker self-association and hence elution
of smaller-mass complexes. So for example, when formulat-
ed with six zinc ions per six insulin molecules, human insulin
eluted with the largest peak corresponding to a mean
22 kDa and insulin degludec with a peak corresponding to
complexes with molecular masses up to at least 5 MDa, but
the insulins eluted with main peaks of lower molecular
weights (371 kDa for insulin degludec and 21 kDa for
human insulin) when formulated with two zinc ions per six
insulin molecules (Table I).
When the SEC-analysis was repeated with addition of
phenol to the elution buffer (simulating the injected formu-
lation), the insulins eluted with a range of values from 81
down to 57 kDa (Table I). The higher values are consistent
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with a dihexameric state (e.g. insulin degludec). For com-
parison, human insulin eluted with a molecular weight
(29 kDa) close to that of an insulin hexamer in the presence
of phenol and six zinc per six insulin molecules.
The correlation between zinc concentration and multi-
hexamer formation of insulin degludec was studied in a
dose–response experiment where formulations ranging from
zero to six zinc ions per six insulin degludec were subjected
to SEC. The fraction of insulin degludec eluted as multi-
hexamers changed from 0 % to almost 100 % across this
increasing range of zinc concentrations, while the converse
was observed for monomers (Fig. 3), demonstrating that as
zinc is depleted the multihexamers likely shorten by disas-
sembly of individual hexamers into monomers. Repetition
of this experiment returned almost identical results (Fig. 3b).
Light-Scattering Studies
Data concerning the molar mass distribution of the peaks for
insulin degludec and octadecandioyl-γ-L-Glu desB30 hu-
man insulin analysed by SEC MALS are shown in Fig. 3.
In the presence of two zinc ions per six insulin molecules,
both analogues show a peak at 78 min, which corresponds
to a monomer–dimer equilibrium, and a peak at around
38 min corresponding to a multihexamer. For degludec, the
maximum height of the multihexamer peak occurred at
2 MDa in this analysis. In the presence of six zinc ions per
six insulin molecules, >95 % of the two analogues eluted at
about 32 min (Fig. 3). For degludec the average molar mass
of this broad peak is 2.9 MDa ranging from 700 kDa to
5 MDa. The corresponding peak for octadecandioyl-γ-L-
Glu desB30 human insulin was a little less broad indicating
a more homogenous size of the multihexamers.
The radius of gyration (Rg) and hydrodynamic radius
(Rh) of the high molecular weight fraction of the two zinc
formulations (Fig. 3) were determined by MALS and DLS,
respectively. In the case of insulin degludec, the respective
values obtained for Rg and Rh were 58 and 21 nm, with
respective values for octadecandioyl-γ-L-Glu desB30 human
of 40 and 16 nm. Hence the ρ parameter, ρ0Rg/Rh, were
2.8 and 2.5, respectively, for insulin degludec and
octadecandioyl-γ-L-Glu desB30 human insulin. This value
indicates long stiff filaments (21). A conformation plot, i.e.
log (Rg) plotted vs. log (Mw), results in a slope of ~0.8 for
both insulin analogues (data not shown) also supporting a
stiff and elongated conformation.
Table I Physicochemical and Pharmacological Characteristics of Study Insulins
Apparent molecular mass (kDa)




















Dodecandioyl-γ-L-Glu T3R3 0.05 120 76 81 57
Tetradecandioyl-γ-L-Glu n.d. 0.1 391 24 75 71
Insulin degludec:
Hexadecandioyl-γ-L-Glu
T3R3 2.4 >5000 371 74 69
Octadecandioyl-γ-L-Glu T3R3 8.7 >5000 1.364 77 69
Hexadecanoyl-γ-L-Glu T3R3 3.5 56 56 70 65
16-hydroxyhexadecanoyl-γ-L-Glu T3R3 0.8 104 58 70 66
Hexadecandioyl-γ-D-Glu T3R3 4.9 422 186 76 67
Hexadecandioyl-α-L-Glu T3R3 2.4 217 79 76 66
Insulin detemir tetradecanoyl R6 1.00 57 30 44 31
Human insulin R6 - 22 21 29 26
HSA Human serum albumin
a Acylated NεB29 - desB30 human insulin
b Samples of 0.6 mM insulin, 10 mM Tris-perchlorat buffer, pH 8.0, 0.6 mM zinc acetate and phenol concentrations varying from 0–30 mM were prepared.
Phenol was added to the insulin solution before zinc acetate
c The association constant Ka for binding of HSA to Lys
B29 (Nε -tetradecanoyl) des-(B30) human insulin (insulin detemir) is 2.4×105 l/mol at room
temperature. Analogue association constants are presented relative to detemir, all values are means of double determination
d Themaximummolecular mass observed after SEC-analysis of 200 μl of 0.6 mM insulin analogue formulated in 1.7% glycerol, 16mMphenol, 16mMm-cresol
and six and two zinc ions per hexamer at 37 °C. The columnwas eluted by 140mMNaCl, 1.54mMNaN3 and 10mMTris–HCl, pH 7.4, at a flow of 0.25ml/min
e SEC-analysis as d but with addition of phenol corresponding to 2 mM to the elution buffer
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Circular Dichroism Spectroscopy Studies
CDS analysis of the insulin zinc hexamer formulations
showed that in the presence of phenol, the analogues
carrying a ligand composed of a fatty acid and glutamic
acid spacer molecule displayed T3R3 conformation
(Table I). With removal of phenol, this changes to T6
conformation. There were some differences between the
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insulins tested in their conformational responses to increas-
ing phenol concentrations from 0 to 30 mM, with most
eventually taking on R6 conformation. Thus, for example,
the response from human insulin changed from −1.5 to
−6.5 Δε (l mol−1 cm−1) at 251 nm (Fig. 4) reflecting a
change in conformational state from T6 through T3R3 to
R6. In contrast, insulin degludec only obtained T3R3 in the
presence of phenol. However insulin degludec did obtain
the R6 conformation in the presence of 100 mM imidazol
and 30 mM resorcinol at pH 7.4.
CDS analysis of the zinc-free formulations of the tested
insulins revealed a large variation in their tendency to
dissociate into insulin monomers. All test insulins remained
as monomers at a concentration up to 1 mM, whereas
LysB29Nε-hexadecanoyl-γ-L-Glu desB30 human insulin
(the fatty mono acid derivative) was monomeric up to
40 μM. Human insulin was monomeric to a concentration
of 0.005 μM) and insulin detemir up to 19 μM (14).
DISCUSSION
The CDS and SEC data show the molecular conformation
and self-association states of the study analogues before and
after injection. As elaborated below, the properties of insulin
degludec emerged in these studies as particularly appealing
for further clinical development.
Firstly, the SEC analysis reveals the extent to which the
insulin analogues were self-associated in environments simu-
lating the pharmaceutical formulation and the subcutaneous
environment. In a pharmaceutical formulation containing
phenol and cresol, and when using a phenol-containing elu-
tion buffer to avoid dissociation of phenol from the insulin
complex, all the formulated insulin analogues eluted primarily
as a single species with a molecular weight corresponding to
the size of an insulin dihexamer (Table I). All the studied
analogues displayed this property apart from insulin detemir,
showing that the glutamic acid linker must be present for
dihexamers to form. Removal of phenol from the elution
buffer during SEC resembles the dilution of phenol after
subcutaneous injection because phenol is a small molecule
that diffuses readily in the tissue and across membranes, in
contrast to the insulin zinc complex. The removal of phenol
during SEC was associated with an increase in the apparent
molecular mass at which some of the analogues eluted. This
effect was particularly marked for insulin degludec and
octadecandioyl-γ-L-Glu desB30 human insulin, both of which
displayed multihexamer formation with an apparent MW
>5 MDa (Table I). Multihexamer formation was impaired,
however, in analogues featuring minor changes of the gluta-
mic spacer molecule compared to degludec. Furthermore, the
terminal carboxylic acid appeared to be critical for multihex-
amer formation since substitution with a hydroxymethyl
group (16-hydroxyhexadecandioyl-γ-L-Glu) or a methyl
group (hexadecanoyl-γ-L-Glu) significantly reducedmultihex-
amer formation. In addition, multihexamer formation was
inhibited by changing attachment of the glutamic acid spacer
molecule to hexadecandioyl-α-L-Glu, or substituting the spac-
er molecule with its D-form (hexadecandioyl-γ-D-Glu). It
therefore appears that multihexamer formation is dependent
on the presence of a diacid of at least 16 carbon atoms
connected to LysB29 of insulin via a γ-L-glutamic acid spacer
molecule.
When the zinc content was reduced in the insulin formu-
lation applied to the SEC column and elution was conducted
Fig. 4 Circular dichroism spectroscopy (CDS) assessment at 251 nm of
the allosteric interconversion of insulin degludec and human insulin with
increasing phenol concentration. The insulin concentration was 0.6 mM
containing six Zn2+ per six insulin degludec and two Zn2+ per six insulin in
Tris-perchlorate 10 mM, pH 8.0. Degludec obtains T3R3 conformation at
10 mM phenol but remains unchanged thereafter. Human insulin obtains
R6 conformation at 30 mM phenol.
Fig. 3 Size exclusion chromatography (SEC) evidence of various insulin
degludec self-association states. Insulin degludec was analysed by SEC in
the absence of phenol employing a Sepharose 6Pc column after formu-
lation with an increasing number of zinc ions per six insulin degludec
molecules (a). The proportion eluting as multihexamers was closely
related to the zinc content. (b) Reciprocal change in the monomer and
multihexamer content going from phenol-containing formulations ranging
from zero to six zinc ions per six insulin degludec molecules. The traces
show the mean and minimum and maximum values (as bars) from
duplicate analyses. Near identical values were obtained in each analysis.
The lowermost trace in panel A shows SEC of an insulin degludec
formulation in the presence of phenol employing a Sepharose 12GL
column. Insulin degludec elutes with a peak corresponding to an insulin
dihexamer. The small peak that elutes at approximately 44 min corre-
sponds to a molecular weight of 118 kDa. The peak at approximately
78 min does not contain protein. (c) shows the molar mass distributions
of insulin degludec and octadecandioyl-γ-L-Glu desB30 human insulin at
two different zinc concentrations in the presence of phenol determined
by SEC-MALS. Solid lines in the chromatograms represent traces from
the RI detector, dotted lines show the molar mass distribution. The buffer
used is without phenol and contains 10 mM Tris–HCl, pH 7.4, 140 mM
NaCl.
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with phenol-free buffer, insulin degludec eluted with a smaller
apparent molecular mass indicating that the multihexamer
complex is dependent on the zinc concentration. This was
confirmed in the zinc dose–response SEC analysis, where, in
the absence of zinc, insulin degludec eluted almost exclusively
as a monomer.
Octadecandioyl-γ-L-Glu desB30 human insulin also elut-
ed at smaller sizes when applied in a formulation with only
two zinc per six insulin molecules, but the apparent molec-
ular mass of the largest elution peak was still in excess of
1.3 MDa, showing that the multihexamer chains of this
analogue are much slower to disassemble, hence the absorp-
tion kinetics of this analogue may to be too long to be
clinically applicable.
When light scattering was used to monitor SEC employ-
ing the six zinc formulation, an almost quantitative forma-
tion of multihexamers was obtained but insulin degludec
displayed a broader MW distribution of higher MW than
octadecandioyl-γ-L-Glu desB30 human insulin. These dif-
ferences might be caused by differences in the kinetics of
formation of the two multihexamers.
The CDS analysis showed that analogues acylated by
ligands composed of a spacer molecule and a fatty acid
readily adopt the T3R3 hexamer conformation in a phar-
maceutical formulation, with the SEC data suggesting that
this species will assemble into dihexamers. Human insulin
and insulin detemir also adopt the T3R3 conformation, but
in contrast they eventually adopt R6 conformation at in-
creasing concentrations of phenol (Fig. 4; 14). In the case of
insulin degludec, the T3R3 dihexamer appears to be highly
stable since in further experiments (analytical ultra centrifu-
gation and CDS, data not shown) this analogue could only
be made to obtain R6 conformation as an insulin-zinc hex-
amer when formulated at neutral pH together with resor-
cinol and imidazol, which bind more tightly to the insulin’s
‘phenol binding pockets’ and are stronger inducers of the R
state than phenol (22).
The CDS and SEC observations suggest that T3R3
dihexamers are held together by the binding of two insulin
hexamer T3 surfaces, and it can be speculated that this is the
result of a single fatty acid contact between these surfaces. In
the case of insulin degludec and octadecandioyl-γ-L-Glu
desB30 human insulin, the change in conformation to T6
enables side chain contacts to be made at each T3 pole of a
hexamer so that the large molecular mass species eluted in
phenol-free SEC likely represent soluble hexamer chains,
with each chain potentially linking hundreds of hexamer
units.
The exact nature of the interaction between hexamers in
the T3R3 dihexamer and the T6 multihexamer is not
known. However, a mechanism that would be plausible
and compatible with the experimental results would involve
coordination of the terminal carboxylic acid residue of the
fatty di-acid chain to a zinc atom in the neighbouring
hexamer. In the multihexamer state, hexamers would there-
fore be joined together in a structure that could be likened,
speculatively, to ‘pearls on a string’, with the fatty acid
chains analogous to the ‘string’ and the zinc ions within
the hexamers being the ‘pearls’. For the T3R3 hexamer, this
mechanism would only allow formation of di-hexamers
because the T3R3 hexamer is only open at one pole hence
a fatty acid coordination would only be feasible by the two
hexamers coming together via their open poles. When the
conformation changes to T6 following dissociation of phe-
nol, the hexamer opens at both poles, and the fatty di-acid
could access zinc atoms in neighbouring hexamers to both
sides, allowing formation of multihexamer chains. This hy-
pothesis is supported by the light scattering data showing
that ρ02.8 (ρ0Rg/Rh ) for insulin degludec; this value is in
good agreement with values obtained for elongated and
relatively stiff molecules (21).
This putative mechanism explains the zinc-dependency
of multihexamer formation, and can also explain why the
fatty acid side chains need to be of a sufficient length and
stereochemical orientation (favouring L-Glu over D-Glu
and gamma-Glu over alpha-Glu for the linker), because a
certain three dimensional orientation would likely be need-
ed for the fatty acid side chain to contact the neighbouring
zinc. Finally, this mechanism would explain why a di-
carboxylic acid can induce multihexamer formation, where-
as a mono-carboxylic acid cannot, since the terminal car-
boxylic acid would be needed for the fatty acid to act as a
ligand with a zinc ion in the insulin hexamer.
Importantly, although ligand-mediated multihexamer
formation leads to high molecular weight insulin analogue-
zinc complexes, all the studied insulin analogues displayed
full solubility as zinc phenol formulations and as multihex-
amers in physiological saline. The soluble state of the insulin
multihexamer is of particular interest from the point of view
of developing formulations for clinical use, since previous
studies have highlighted the advantages of a soluble depot
over a depot composed of precipitate particles with respect
to reproducible absorption kinetics after subcutaneous in-
jection (5,23).
It is important to note that the formation of complicated
structures like the insulin degludec multihexamer is likely to
be sensitive to the environment during the time of forma-
tion. Thus, a previous study employing analytical ultra
centrifugation reported a molecular weight of 44MDa (24).
The present investigation can only suggest that the multi-
hexamers are large structures, likely comprising several
hundred hexamer units. The exact size of multihexamer
chains formed in vivo at the site of subcutaneous injection
remains elusive. In future studies, further analysis of larger
aggregates using other types of methodologies should be
performed (25). Large-sized protein-like structures could
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potentially evoke immunological responses, and this issue is
relevant, for example, for antibody-based therapeutics for
which neutralising antibodies can impact efficacy over time
(26). Aggregates of endogenous proteins, particularly when
denatured, may also induce an immunological response
(27). Therefore, the phase 3 clinical studies of insulin deglu-
dec, in which have been included close to 10,000 patients,
have collected data on antibody formation and injection site
reactions. Available data are reassuring, showing that, for all
participants, the level of insulin degludec-specific antibodies
was close to, or below, the limit of detection at screening and
remained at the same level after 16 weeks of treatment
(28,29). Furthermore, dermatological injection site reactions
occurred only rarely in these studies with no evidence of an
increased incidence vs. insulin glargine.
The CDS analyses in zinc-free formulations show that
the test analogues, including insulin degludec, are mono-
mers at concentrations higher than 1 mM, which means that
once multihexamers dissociate due to zinc diffusion, the
liberated dimers will immediately dissociate into monomers.
This is likely to be the state in which insulin degludec is
absorbed into the circulation, since monomers of insulin
pass faster through the tissue and across membranes than
higher molecular weight complexes.
A potentially important consequence of the property of
forming very stable T3R3 dihexamers in a pharmaceutical
formulation (and multihexamers at the site of injection) is
that other insulins (e.g. rapid-acting insulins) can be co-
formulated without the risk of inter-exchange of monomers
to form hybrid hexamers either in the cartridge or injection
depot. This could enable the development of combination
products with discrete preservation of the PK profiles of the
component insulins. Indeed, a co-formulation of insulin
degludec plus insulin aspart is currently undergoing clinical
investigation (30).
In summary, insulin degludec and octadecandioyl-γ-L-
Glu desB30 human insulin stood out in our analyses as
compounds able to form multihexamer chains following
subcutaneous injection, and insulin degludec further stood
out as suitable for clinical development due to a favourable
PK/PD profile with a plasma t½ of 25 h in humans in
subsequent studies. It can be concluded that insulin deglu-
dec has a unique mechanism of protraction; in the presence
of phenol and zinc, (as in a pharmaceutical formulation) it
forms a soluble and stable dihexamer, but after injection, as
phenol diffuses away, this re-organises to form multi-
hexamer chains that will have a long residence time at the
injection depot. With the gradual diffusion of zinc, however,
these chains are expected to gradually disassemble to release
monomers from the terminal ends of multihexamers since
the zinc ions of the terminal ends are exposed due to their
T3 conformation (Fig. 5). Further studies are required to
investigate the kinetics of the multihexamer dissociation
process in vivo as the rate-limiting step in the absorption of
insulin degludec from the subcutaneous depot into the cir-
culation. In contrast to other basal insulins, the release of
monomers would become the rate-limiting step in absorp-
tion rather than, e.g. depot blood flow, and this might limit
Fig. 5 Schematic representation
of the hypothesis for the mode of
retarded absorption of insulin
degludec: Insulin degludec is
injected subcutaneously as a zinc
phenol formulation containing
insulin degludec dihexamer in the
T3R3 conformation. Rapid loss of
phenol changes the degludec
hexamers to T6 configuration and
multi-hexamer chains form. With
slow diffusion of zinc, these chains
break down into dimers, which
quickly dissociate into readily-
absorbed monomers.
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variability in PD response. Furthermore, the affinity for
albumin is likely to buffer any variability that does occur
in absorption rate through the mechanisms described pre-
viously for insulin detemir by Kurtzhals (31). Indeed, the
glucose-lowering variability profile of degludec has been
shown to be superior to that of insulin glargine (32).
The pharmacological consequence of this protraction
mechanism in terms of the time-action profile are shown
by PK and PD data (24,33,34). These demonstrate that in
clinical use, insulin degludec has a duration of blood-glucose
lowering action that extends beyond 42 h (33), and hence
insulin degludec reaches steady-state with daily dosing to
produce a flat and stable PK/PD profile (24,34). Clinical
results obtained so far show that the ultra-long and flat
action profile of insulin degludec can offer greater flexibility
of dosing and a reduced risk of nocturnal hypoglycaemia
compared to other basal insulins (28,29,35).
CONCLUSION
In conclusion, it is possible to engineer insulin analogues that
can self-associate into a multihexameric state after injection.
This was accomplished by attaching a C16 or C18 dicarbox-
ylic acid via a γ-glutamic acid spacer to the ε-amino group of
the B29 lysine residue of desB30 human insulin. As shown
herein, this capability is critically dependent on the specific
composition of the fatty acid and spacer complex, and there-
fore shared by few insulin analogues. The resultant PD profile
of this mechanism is highly promising from the perspective of
developing an improved basal insulin fulfilling the criteria of
more than 24-hour duration of action with little variability
over the day and from day-to-day, and providing an option
for co-formulation with rapid-acting insulin.
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